Author

Alain M. Schoepfer

Going Beyond Eosinophils in Eosinophilic Esophagitis (EoE): The Importance of Type 2 Inflammation and Evolving Approaches to Clinical Management (Sanofi Genzyme and Regeneron)
Going Beyond Eosinophils in Eosinophilic Esophagitis (EoE): The Importance of Type 2 Inflammation and Evolving Approaches to Clinical Management (Sanofi Genzyme and Regeneron)

Alain M. Schoepfer  et al.

SYMPTOM AND QUALITY OF LIFE BURDEN AMONG PATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING
SYMPTOM AND QUALITY OF LIFE BURDEN AMONG PATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING

SYMPTOM AND QUALITY OF LIFE BURDEN AMONG PATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING
SYMPTOM AND QUALITY OF LIFE BURDEN AMONG PATIENTS WITH EOSINOPHILIC OESOPHAGITIS IN A REAL-WORLD SETTING

Alain M. Schoepfer  et al.

A Deeper Dive Into the Clinical Implications of Type 2 Inflammation in EoE and Approaches to Patient Care (Sanofi)
A Deeper Dive Into the Clinical Implications of Type 2 Inflammation in EoE and Approaches to Patient Care (Sanofi)

Alain M. Schoepfer  et al.

IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT
IMPACT OF OVERWEIGHT AND OBESITY ON DISEASE OUTCOME IN THE PEDIATRIC SWISS IBD COHORT

Alain M. Schoepfer  et al.

DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY
DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY

Alain M. Schoepfer  et al.

A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE
A SURVEY BASED ASSESSMENT OF MANAGEMENT OF ESOPHAGEAL FOOD IMPACTIONS IN THE US AND EUROPE

Alain M. Schoepfer  et al.

SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY
SEX IMPACTS ENDOSCOPIC AND HISTOLOGICAL DISEASE ACTIVITY BUT NOT SYMPTOMS OR QUALITY OF LIFE IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS OF A NATIONWIDE PROSPECTIVE COHORT STUDY

Alain M. Schoepfer  et al.

ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY
ODYNOPHAGIA AND RETROSTERNAL PAIN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – RATHER INDICATIVE OF DISEASE ACTIVITY THAN SIDE EFFECT OF THERAPY

Alain M. Schoepfer  et al.

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults

Alain M. Schoepfer  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWINGTHE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alain M. Schoepfer  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE ABLE TO MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE FIRST 48-WEEKS OPEN-LABEL EXTENSION PHASE OF THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Alain M. Schoepfer  et al.

BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL
BUDESONIDE ORODISPERSIBLE TABLETS ARE HIGHLY EFFECTIVE FOR RE-INDUCTION OF CLINICAL REMISSION IN RELAPSING ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE EOS-2 TRIAL

Alain M. Schoepfer  et al.

A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
A 12-WEEK TREATMENT WITH BUDESONIDE ORODISPERSIBLE TABLETS IN THE EOS-1 TRIAL FOR INCOMPLETE RESPONDERS SIGNIFICANTLY IMPROVES BOTH INFLAMMATORY AND FIBROSTENOTIC ENDOSCOPIC FEATURES IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

Alain M. Schoepfer  et al.

Item 1 - 14 / 14
1